154 related articles for article (PubMed ID: 9246959)
1. Markers of intravascular coagulation and fibrinolysis in preeclampsia: association with intrauterine growth retardation.
Schjetlein R; Haugen G; Wisløff F
Acta Obstet Gynecol Scand; 1997 Jul; 76(6):541-6. PubMed ID: 9246959
[TBL] [Abstract][Full Text] [Related]
2. Hemostatic variables as independent predictors for fetal growth retardation in preeclampsia.
Schjetlein R; Abdelnoor M; Haugen G; Husby H; Sandset PM; Wisløff F
Acta Obstet Gynecol Scand; 1999 Mar; 78(3):191-7. PubMed ID: 10078579
[TBL] [Abstract][Full Text] [Related]
3. Coagulation and fibrinolytic parameters in normal pregnancy and in pregnancy complicated by intrauterine growth retardation.
Bellart J; Gilabert R; Fontcuberta J; Carreras E; Miralles RM; Cabero L
Am J Perinatol; 1998 Feb; 15(2):81-5. PubMed ID: 9514130
[TBL] [Abstract][Full Text] [Related]
4. Coagulation and fibrinolysis in preeclampsia and neonates.
Tanjung MT; Siddik HD; Hariman H; Koh SC
Clin Appl Thromb Hemost; 2005 Oct; 11(4):467-73. PubMed ID: 16244774
[TBL] [Abstract][Full Text] [Related]
5. Fibrinolysis parameters in Sudanese women with severe preeclampsia.
Elzein HO; Muddathir AR; Rida M; Rayis DA; Elhassan EM; Adam I
Hypertens Pregnancy; 2016 Nov; 35(4):559-564. PubMed ID: 27598010
[TBL] [Abstract][Full Text] [Related]
6. Fibrinolysis during normal pregnancy and severe preeclampsia relationships between plasma levels of plasminogen activators and inhibitors.
Nakashima A; Kobayashi T; Terao T
Gynecol Obstet Invest; 1996; 42(2):95-101. PubMed ID: 8878712
[TBL] [Abstract][Full Text] [Related]
7. Fibrinolytic parameters in normotensive pregnancy with intrauterine fetal growth retardation and in severe preeclampsia.
Estellés A; Gilabert J; España F; Aznar J; Galbis M
Am J Obstet Gynecol; 1991 Jul; 165(1):138-42. PubMed ID: 1906680
[TBL] [Abstract][Full Text] [Related]
8. Studies of blood coagulation-fibrinolysis regarding kallikrein-kinin system in severe preeclampsia.
Mutoh S; Kobayashi M; Hirata J; Itoh N; Maki M; Komatsu Y; Yoshida A; Sasa H; Kuroda K; Kikuchi Y
Agents Actions Suppl; 1992; 38 ( Pt 2)():342-9. PubMed ID: 1462840
[TBL] [Abstract][Full Text] [Related]
9. Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation.
Estellés A; Gilabert J; Keeton M; Eguchi Y; Aznar J; Grancha S; Espña F; Loskutoff DJ; Schleef RR
Blood; 1994 Jul; 84(1):143-50. PubMed ID: 8018914
[TBL] [Abstract][Full Text] [Related]
10. Coagulofibrinolytic changes in patients with disseminated intravascular coagulation associated with post-cardiac arrest syndrome--fibrinolytic shutdown and insufficient activation of fibrinolysis lead to organ dysfunction.
Wada T; Gando S; Mizugaki A; Yanagida Y; Jesmin S; Yokota H; Ieko M
Thromb Res; 2013 Jul; 132(1):e64-9. PubMed ID: 23726093
[TBL] [Abstract][Full Text] [Related]
11. Preeclampsia as chronic disseminated intravascular coagulation. Study of two parameters: thrombin-antithrombin III complex and D-dimers.
Kobayashi T; Terao T
Gynecol Obstet Invest; 1987; 24(3):170-8. PubMed ID: 3319818
[TBL] [Abstract][Full Text] [Related]
12. Increased blood flow resistance in placental circulation and levels of plasminogen activator inhibitors types 1 and 2 in severe preeclampsia.
He S; Bremme K; Blombäck M
Blood Coagul Fibrinolysis; 1995 Dec; 6(8):703-8. PubMed ID: 8825219
[TBL] [Abstract][Full Text] [Related]
13. Haemostatic, fibrinolytic and endothelial variables in normal pregnancies and pre-eclampsia.
Halligan A; Bonnar J; Sheppard B; Darling M; Walshe J
Br J Obstet Gynaecol; 1994 Jun; 101(6):488-92. PubMed ID: 8018635
[TBL] [Abstract][Full Text] [Related]
14. Preeclampsia: haemostatic status and the short-term effects of methyldopa and isradipine therapy.
Yin KH; Koh SC; Malcus P; SvenMontan S; Biswas A; Arulkumaran S; Ratnam SS
J Obstet Gynaecol Res; 1998 Jun; 24(3):231-8. PubMed ID: 9714995
[TBL] [Abstract][Full Text] [Related]
15. Fibrinolytic Changes in Women with Preeclampsia.
Godtfredsen AC; Sidelmann JJ; Dolleris BB; Jørgensen JS; Johansen EKJ; Pedersen MFB; Palarasah Y; Gram JB
Clin Appl Thromb Hemost; 2022; 28():10760296221126172. PubMed ID: 36217728
[TBL] [Abstract][Full Text] [Related]
16. Changes in the plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia.
Estellés A; Gilabert J; Aznar J; Loskutoff DJ; Schleef RR
Blood; 1989 Sep; 74(4):1332-8. PubMed ID: 2504307
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activators, plasminogen activator inhibitors and markers of intravascular coagulation in pre-eclampsia.
Koh SC; Anandakumar C; Montan S; Ratnam SS
Gynecol Obstet Invest; 1993; 35(4):214-21. PubMed ID: 8330765
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator of urokinase type and its inhibitor of placental type in hypertensive pregnancies and in intrauterine growth retardation: possible markers of placental function.
Lindoff C; Astedt B
Am J Obstet Gynecol; 1994 Jul; 171(1):60-4. PubMed ID: 8030735
[TBL] [Abstract][Full Text] [Related]
19. Significance of the plasminogen activator inhibitor of placental type (PAI-2) in pregnancy.
Astedt B; Lindoff C; Lecander I
Semin Thromb Hemost; 1998; 24(5):431-5. PubMed ID: 9834009
[TBL] [Abstract][Full Text] [Related]
20. Increased placental antifibrinolytic potential and fibrin deposits in pregnancy-induced hypertension and preeclampsia.
Kanfer A; Bruch JF; Nguyen G; He CJ; Delarue F; Flahault A; Nessmann C; Uzan S
Lab Invest; 1996 Jan; 74(1):253-8. PubMed ID: 8569189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
